MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma.
A computational approach developed by researchers at MD Anderson Cancer Center combines data from parallel gene-expression profiling methods to create spatial maps of a given tissue at single-cell resolution. The resulting maps can provide insights into the cancer microenvironment and other tissue types.
An outreach program at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) is mailing free at-home colon cancer screening tests to Black primary care patients who have not yet had their routine colonoscopy.
A UPMC-led study suggests that healthcare professionals exposed to SARS-CoV-2 can safely return to work after seven days of quarantine if they are asymptomatic and receive a negative COVID-19 test. The findings, from the first reported study evaluating reduced quarantine duration in a healthcare setting, offer a potential new strategy for mitigating staffing shortages prior to a next wave of COVID-19 cases.
The NCI-MATCH trial offers treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm (Z1M) is evaluating the immunotherapy combination of relatlimab and nivolumab in patients whose tumors have mismatch repair deficiency and LAG-3 expression and have progressed after anti–PD-1/PD-L1 immunotherapy.
A study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) conducted an extensive review of both peer-reviewed research studies and governmental public health data, looking at the so-called “intersectionality” of factors influencing health disparities to determine that sexual and racial minority status influences cancer screening behaviors and cancer risk.
Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Scientists at Yale Cancer Center have discovered consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
A study out of Ontario, Canada found an immediate cancer diagnosis decrease of 34% in March 2020, followed by a slow and incomplete recovery.
